Document is current
Any future updates will be listed below
-
Authors
Ojaniemi, Iida https://orcid.org/0000-0001-8309-6703
Salmivesi, Susanna
Tikkakoski, Antti https://orcid.org/0000-0003-4706-9673
Karjalainen, Jussi https://orcid.org/0000-0001-8747-7087
Lehtimäki, Lauri https://orcid.org/0000-0003-1586-4998
Schultz, Rüdiger https://orcid.org/0000-0002-7354-5066
-
Funding
Funding for this research was provided by:
Sydämen asialla
Tampereen Tuberkuloosisäätiö
- License Information
-
More Information
Article History
Received: 3 August 2022
Accepted: 16 November 2022
First Online: 30 November 2022
Declarations
:
: According to local legislations, evaluation by the ethical board is not needed for retrospective chart reviews, and the study was approved as such by the Tampere University Hospital.
: Not applicable.
: Professor Lehtimäki has received personal fees for lectures, consultations or advisory boards from ALK, AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, GSK, Mundipharma, Novartis, Orion Pharma and Sanofi.
